Importer of Controlled Substances Notice of Registration, 3160 [2011-942]

Download as PDF 3160 Federal Register / Vol. 76, No. 12 / Wednesday, January 19, 2011 / Notices Web site: https://www.usdoj.gov/enrd/ Consent_Decrees.html. A copy of the proposed consent decree may also be obtained by mail from the Consent Decree Library, P.O. Box 7611, U.S. Department of Justice, Washington, DC 20044–7611 or by faxing or e-mailing a request to Tonia Fleetwood (tonia.fleetwood@usdoj.gov), fax no. (202) 514–0097, phone confirmation number (202) 514–1547. In requesting a copy from the Consent Decree Library, please enclose a check in the amount of $26.50 (25 cents per page reproduction cost) payable to the U.S. Treasury or, if by e-mail or fax, forward a check in that amount to the Consent Decree Library at the stated address. Maureen M. Katz, Assistant Chief, Environmental Enforcement Section, Environment and Natural Resources Division. [FR Doc. 2011–973 Filed 1–18–11; 8:45 am] BILLING CODE 4410–15–P DEPARTMENT OF JUSTICE Drug Enforcement Administration mstockstill on DSKH9S0YB1PROD with NOTICES Importer of Controlled Substances; Notice of Registration By Notice dated May 28, 2010 and published in the Federal Register on June 8, 2010, (75 FR 32504), Stepan Company, Natural Products Department, 100 W. Hunter Avenue, Maywood, New Jersey 07607, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as an importer of Coca Leaves (9040), a basic class of controlled substance listed in schedule II. The company plans to import the listed controlled substance for the manufacture of a bulk controlled substance for distribution to its customer. No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a) and 952(a) and determined that the registration of Stepan Company to import the basic class of controlled substance is consistent with the public interest and with United States obligations under international treaties, conventions, or protocols in effect on May 1, 1971. DEA has investigated Stepan Company to ensure that the company’s registration is consistent with the public interest. The investigation has included inspection and testing of the company’s physical security systems, verification of the company’s compliance with state and local laws, and a review of the company’s background and history. Therefore, pursuant to 21 U.S.C. 952(a) VerDate Mar<15>2010 17:04 Jan 18, 2011 Jkt 223001 and 958(a), and in accordance with 21 CFR 1301.34, the above named company is granted registration as an importer of the basic class of controlled substance listed. Dated: December 20, 2010. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. Dated: December 20, 2010. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. 2011–942 Filed 1–18–11; 8:45 am] [FR Doc. 2011–939 Filed 1–18–11; 8:45 am] BILLING CODE 4410–09–P DEPARTMENT OF JUSTICE BILLING CODE 4410–09–P Drug Enforcement Administration DEPARTMENT OF JUSTICE Manufacturer of Controlled Substances; Notice of Registration Drug Enforcement Administration Importer of Controlled Substances Notice of Registration By Notice dated May 28, 2010, and published in the Federal Register on June 8, 2010 (75 FR 32505), Meda Pharmaceuticals, Inc. 705 Eldorado Street, Decatur, Illinois 62523, made application by letter to the Drug Enforcement Administration (DEA) to be registered as an importer of Nabilone (7379), a basic class of controlled substance listed in schedule II. The company plans to import the listed controlled substance as a finished drug product in dosage form only for distribution to its customers. The company does not import the listed controlled substance in bulk active pharmaceutical ingredient (API) form. There are no domestic sources of Nabilone in finished drug product form available in the United States. The U.S. Food and Drug Administration has approved this product for medical use in the United States. No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a) and § 952(a), and determined that the registration of Meda Pharmaceuticals Inc. to import the basic classes of controlled substances is consistent with the public interest, and with United States obligations under international treaties, conventions, or protocols in effect on May 1, 1971. DEA has investigated Meda Pharmaceuticals Inc. to ensure that the company’s registration is consistent with the public interest. The investigation has included inspection and testing of the company’s physical security systems, verification of the company’s compliance with state and local laws, and a review of the company’s background and history. Therefore, pursuant to 21 U.S.C. 952(a) and § 958(a), and in accordance with 21 CFR 1301.34, the above named company is granted registration as an importer of the basic classes of controlled substances listed. PO 00000 Frm 00086 Fmt 4703 Sfmt 9990 By Notice dated April 20, 2010 and published in the Federal Register on April 26, 2010, (75 FR 21661), Stepan Company, Natural Products Department, 100 W. Hunter Avenue, Maywood, New Jersey 07607, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the basic classes of controlled substances: Drug Cocaine (9041) ............................. Benzoylecgonine (9180) ............... Schedule II II The company plans to manufacture the listed controlled substances in bulk for distribution to its customers. No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a) and determined that the registration of Stepan Company to manufacture the listed basic classes of controlled substances is consistent with the public interest at this time. DEA has investigated Stepan Company to ensure that the company’s registration is consistent with the public interest. The investigation has included inspection and testing of the company’s physical security systems, verification of the company’s compliance with state and local laws, and a review of the company’s background and history. Therefore, pursuant to 21 U.S.C. 823(a), and in accordance with 21 CFR 1301.33, the above named company is granted registration as a bulk manufacturer of the basic classes of controlled substances listed. Dated: December 20, 2010. Joseph T. Rannazzisi, Deputy Assistant Administrator Office of Diversion Control, Drug Enforcement Administration. [FR Doc. 2011–940 Filed 1–18–11; 8:45 am] BILLING CODE 4410–09–P E:\FR\FM\19JAN1.SGM 19JAN1

Agencies

[Federal Register Volume 76, Number 12 (Wednesday, January 19, 2011)]
[Notices]
[Page 3160]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2011-942]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Importer of Controlled Substances Notice of Registration

    By Notice dated May 28, 2010, and published in the Federal Register 
on June 8, 2010 (75 FR 32505), Meda Pharmaceuticals, Inc. 705 Eldorado 
Street, Decatur, Illinois 62523, made application by letter to the Drug 
Enforcement Administration (DEA) to be registered as an importer of 
Nabilone (7379), a basic class of controlled substance listed in 
schedule II.
    The company plans to import the listed controlled substance as a 
finished drug product in dosage form only for distribution to its 
customers. The company does not import the listed controlled substance 
in bulk active pharmaceutical ingredient (API) form.
    There are no domestic sources of Nabilone in finished drug product 
form available in the United States. The U.S. Food and Drug 
Administration has approved this product for medical use in the United 
States.
    No comments or objections have been received. DEA has considered 
the factors in 21 U.S.C. 823(a) and Sec.  952(a), and determined that 
the registration of Meda Pharmaceuticals Inc. to import the basic 
classes of controlled substances is consistent with the public 
interest, and with United States obligations under international 
treaties, conventions, or protocols in effect on May 1, 1971. DEA has 
investigated Meda Pharmaceuticals Inc. to ensure that the company's 
registration is consistent with the public interest. The investigation 
has included inspection and testing of the company's physical security 
systems, verification of the company's compliance with state and local 
laws, and a review of the company's background and history. Therefore, 
pursuant to 21 U.S.C. 952(a) and Sec.  958(a), and in accordance with 
21 CFR 1301.34, the above named company is granted registration as an 
importer of the basic classes of controlled substances listed.

     Dated: December 20, 2010.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. 2011-942 Filed 1-18-11; 8:45 am]
BILLING CODE 4410-09-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.